Is romosozumab (Evenity) safe to use in patients with liver cirrhosis?

Evenity Safety in Liver Cirrhosis

There is no specific safety data available for romosozumab (Evenity) use in patients with liver cirrhosis, and it should be used with extreme caution or avoided in this population until more evidence becomes available.

Critical Evidence Gap

The FDA drug label for Evenity 1 provides comprehensive safety information for renal impairment but contains no specific data or recommendations regarding hepatic impairment or liver cirrhosis. This represents a significant knowledge gap for clinical decision-making.

Key Safety Considerations

Lack of Hepatic Impairment Data

• The Evenity prescribing information does not include pharmacokinetic studies in patients with hepatic impairment 1
• No dose adjustments are specified for liver disease, unlike the detailed guidance provided for renal impairment 1
• Clinical trials excluded patients with significant hepatic dysfunction

Metabolic Profile

Romosozumab is a humanized monoclonal antibody (IgG2) that binds and inhibits sclerostin 1. As a large protein molecule:

• It is not metabolized by hepatic cytochrome P450 enzymes
• Elimination occurs primarily through protein catabolism rather than hepatic metabolism
• This suggests that mild to moderate hepatic impairment may not significantly alter drug clearance

Specific Risks in Cirrhosis

Hypocalcemia Risk: Patients with cirrhosis may have:

• Altered vitamin D metabolism
• Malabsorption issues
• Hypoalbuminemia affecting calcium binding
• Evenity can cause hypocalcemia, which occurred in 0.2% of treated patients 1
• This risk may be amplified in cirrhotic patients with baseline nutritional deficiencies

Cardiovascular Concerns: The FDA label warns about increased cardiovascular risk 2:

• Patients with cirrhosis often have cirrhotic cardiomyopathy
• Portal hypertension creates hemodynamic alterations
• The combination may increase vulnerability to cardiovascular adverse events

Injection Site Reactions: Occurred in 4.9% of patients 1:

• Cirrhotic patients may have coagulopathy
• Thrombocytopenia is common in advanced cirrhosis
• Increased bleeding risk at injection sites

Clinical Approach

If Evenity Must Be Considered:

1. Severity Assessment:

   • Use only in Child-Pugh A (compensated) cirrhosis if absolutely necessary
   • Avoid in Child-Pugh B or C cirrhosis due to unknown safety profile

2. Pre-treatment Evaluation:

   • Measure baseline serum calcium, albumin, and vitamin D levels
   • Assess cardiovascular risk factors thoroughly
   • Evaluate platelet count and coagulation parameters
   • Screen for varices and portal hypertension severity

3. Monitoring Protocol:

   • Check serum calcium at baseline, week 2, and monthly 1
   • Ensure adequate calcium (1000 mg daily) and vitamin D (400-800 IU daily) supplementation
   • Monitor for injection site complications more frequently
   • Assess cardiovascular status regularly

4. Alternative Considerations:

   • Bisphosphonates have more established safety data in liver disease 3
   • Denosumab may be preferable as it also avoids hepatic metabolism
   • Consider these alternatives first unless contraindicated

Evidence from General Cirrhosis Pharmacology

Research on medication safety in cirrhosis 4, 5, 6 emphasizes that:

• Drugs not metabolized by the liver are generally safer in cirrhosis
• However, pharmacodynamic alterations (how the body responds to the drug) can still occur
• Increased susceptibility to adverse effects is common even with drugs not requiring hepatic metabolism 3, 7

Common Pitfalls to Avoid

• Do not assume safety based solely on non-hepatic metabolism
• Do not use in decompensated cirrhosis (Child-Pugh B/C) without compelling evidence
• Do not neglect calcium supplementation - this is critical and may need higher doses than standard
• Do not ignore cardiovascular screening - the FDA warning about MI/stroke risk is particularly relevant in cirrhosis

Bottom Line

Given the absence of safety data, lack of pharmacokinetic studies in hepatic impairment, and the availability of alternative osteoporosis treatments with better-established safety profiles in liver disease, Evenity should generally be avoided in patients with liver cirrhosis. If use is deemed absolutely necessary in a patient with compensated (Child-Pugh A) cirrhosis and very high fracture risk, proceed only with intensive monitoring, adequate supplementation, and careful cardiovascular assessment. Consider alternative therapies first, particularly bisphosphonates or denosumab, which have more clinical experience in this population 3, 8.